Literature DB >> 22573593

Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.

Derek J Sloan1, Elizabeth L Corbett, Anthony E Butterworth, Henry C Mwandumba, Saye H Khoo, Aaron Mdolo, Doris Shani, Mercy Kamdolozi, Jenny Allen, Denis A Mitchison, David J Coleman, Geraint R Davies.   

Abstract

Serial Sputum Colony Counting (SSCC) is an important technique in clinical trials of new treatments for tuberculosis (TB). Quantitative cultures on selective Middlebrook agar are used to calculate the rate of bacillary elimination from sputum collected from patients at different time points during the first 2 months of therapy. However, the procedure can be complicated by high sample contamination rates. This study, conducted in a resource-poor setting in Malawi, assessed the ability of different antifungal drugs in selective agar to reduce contamination. Overall, 229 samples were studied and 15% to 27% were contaminated. Fungal organisms were particularly implicated, and samples collected later in treatment were at particular risk (P < 0.001). Amphotericin B (AmB) is the standard antifungal drug used on SSCC plates at a concentration of 10 mg/ml. On selective Middlebrook 7H10 plates, AmB at 30 mg/ml reduced sample contamination by 17% compared with AmB at 10 mg/ml. The relative risk of contamination using AmB at 10 mg/ml was 1.79 (95% confidence interval [CI], 1.25 to 3.55). On Middlebrook 7H11 plates, a combination of AmB at 10 mg/ml and carbendazim at 50 mg/ml was associated with 10% less contamination than AmB at 30 mg/ml. The relative risk of contamination with AmB at 30 mg/ml was 1.79 (95% CI, 1.01 to 3.17). Improved antifungal activity was accompanied by a small reduction in bacillary counts, but this did not affect modeling of bacillary elimination. In conclusion, a combination of AmB and carbendazim optimized the antifungal activity of selective media for growth of TB. We recommend this method to reduce contamination rates and improve SSCC studies in African countries where the burden of TB is highest.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573593      PMCID: PMC3405637          DOI: 10.1128/JCM.00043-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.

Authors:  G R Davies; S H Khoo; L J Aarons
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

2.  Response of soil bacterial community to repeated applications of carbendazim.

Authors:  Xiuguo Wang; Min Song; Yiqi Wang; Chunming Gao; Qun Zhang; Xiaoqiang Chu; Hua Fang; Yunlong Yu
Journal:  Ecotoxicol Environ Saf       Date:  2011-08-27       Impact factor: 6.291

3.  Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

Authors:  N Kennedy; L Berger; J Curram; R Fox; J Gutmann; G M Kisyombe; F I Ngowi; A R Ramsay; A O Saruni; N Sam; G Tillotson; L O Uiso; M Yates; S H Gillespie
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  Activity of amoxicillin/clavulanate in patients with tuberculosis.

Authors:  H F Chambers; T Kocagöz; T Sipit; J Turner; P C Hopewell
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

5.  Stability of amphotericin B in infusion bottles.

Authors:  E R Block; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

6.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Authors:  R Rustomjee; C Lienhardt; T Kanyok; G R Davies; J Levin; T Mthiyane; C Reddy; A W Sturm; F A Sirgel; J Allen; D J Coleman; B Fourie; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2008-02       Impact factor: 2.373

7.  Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation.

Authors:  Louis Grandjean; Laura Martin; Robert H Gilman; Teresa Valencia; Beatriz Herrera; Willi Quino; Eric Ramos; Maribel Rivero; Rosario Montoya; A Roderick Escombe; David Coleman; Denis Mitchison; Carlton A Evans
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

8.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

Authors:  Marcus B Conde; Anne Efron; Carla Loredo; Gilvan R Muzy De Souza; Nadja P Graça; Michelle C Cezar; Malathi Ram; Mohammad A Chaudhary; William R Bishai; Afranio L Kritski; Richard E Chaisson
Journal:  Lancet       Date:  2009-04-04       Impact factor: 79.321

9.  Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture.

Authors:  R L Peres; E L Maciel; C G Morais; F C K Ribeiro; S A Vinhas; C Pinheiro; R Dietze; J L Johnson; K Eisenach; M Palaci
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

10.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis.

Authors:  R Brindle; J Odhiambo; D Mitchison
Journal:  BMC Pulm Med       Date:  2001       Impact factor: 3.317

View more
  10 in total

1.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

2.  Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Authors:  Sandeep Tyagi; Nicole C Ammerman; Si-Yang Li; John Adamson; Paul J Converse; Rosemary V Swanson; Deepak V Almeida; Jacques H Grosset
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

Review 3.  The role of delamanid in the treatment of drug-resistant tuberculosis.

Authors:  Joseph M Lewis; Derek J Sloan
Journal:  Ther Clin Risk Manag       Date:  2015-05-13       Impact factor: 2.423

4.  Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.

Authors:  Derek J Sloan; Henry C Mwandumba; Natalie J Garton; Saye H Khoo; Anthony E Butterworth; Theresa J Allain; Robert S Heyderman; Elizabeth L Corbett; Mike R Barer; Geraint R Davies
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

5.  Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB.

Authors:  David A Barr; Mercy Kamdolozi; Yo Nishihara; Victor Ndhlovu; Margaret Khonga; Geraint R Davies; Derek J Sloan
Journal:  Tuberculosis (Edinb)       Date:  2016-03-23       Impact factor: 3.131

6.  Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy.

Authors:  Mohamed I M Ahmed; Nyanda E Ntinginya; Gibson Kibiki; Bariki A Mtafya; Hadija Semvua; Stellah Mpagama; Charles Mtabho; Elmar Saathoff; Kathrin Held; Rebecca Loose; Inge Kroidl; Mkunde Chachage; Ulrich von Both; Antelmo Haule; Anna-Maria Mekota; Martin J Boeree; Stephen H Gillespie; Michael Hoelscher; Norbert Heinrich; Christof Geldmacher
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

7.  Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis.

Authors:  Sumona Datta; Keren Alvarado; Robert H Gilman; Teresa Valencia; Christian Aparicio; Eric S Ramos; Rosario Montoya; Carlton A Evans
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

8.  Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment.

Authors:  Benjawan Kaewseekhao; Vivek Naranbhai; Sittiruk Roytrakul; Wises Namwat; Atchara Paemanee; Viraphong Lulitanond; Angkana Chaiprasert; Kiatichai Faksri
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

Review 9.  Quality of outcome reporting in phase II studies in pulmonary tuberculosis.

Authors:  Laura Jayne Bonnett; Geraint Rhys Davies
Journal:  Trials       Date:  2015-11-14       Impact factor: 2.279

Review 10.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.